In phase 3 trials, the MC4R agonist peptide setmelanotide achieved at least 10% weight loss in 80% of POMC-deficient and 45% of LEPR-deficient patients, while dramatically reducing hunger scores.
80% achieved ≥10% weight loss (POMC trial)In patients with lifelong severe genetic obesity who had no previous effective treatment, setmelanotide produced clinically meaningful weight loss and dramatically reduced hunger
What the researchers found
In the POMC deficiency trial (n=10): 80% of participants achieved at least 10% weight loss at approximately 1 year. Mean hunger score reduction was -27.1% (p=0.0005).
In the LEPR deficiency trial (n=11): 45% of participants achieved at least 10% weight loss. Mean hunger score reduction was -43.7% (p<0.0001).
During the placebo-controlled withdrawal phase, symptoms returned when patients were switched to placebo, confirming the drug's direct effect. Most common adverse events were injection site reactions and hyperpigmentation (skin darkening). No serious treatment-related adverse events occurred in either trial.
Why it matters
Before setmelanotide, people with POMC or LEPR deficiency had no treatment that addressed the root cause of their obesity — a broken melanocortin signaling pathway. These patients experience relentless, overwhelming hunger that no amount of willpower can overcome. Setmelanotide directly activates the downstream receptor, restoring appetite control. This represents one of the clearest examples of precision medicine in obesity treatment.
How the study worked
Two single-arm, open-label, multicentre phase 3 trials conducted across 10 hospitals in the US, Canada, and Europe. Patients aged 6+ with confirmed POMC or LEPR deficiency received setmelanotide for 12 weeks. Those with meaningful weight loss entered an 8-week blinded withdrawal (4 weeks drug, 4 weeks placebo), then 32 weeks more of open-label treatment. Primary endpoint: proportion achieving ≥10% weight loss at ~1 year.
What this study cannot tell us
Very small sample sizes (10 and 11 patients) — inherent to studying extremely rare genetic conditions. The trials were open-label for most of their duration, which could bias weight and hunger assessments. The blinded withdrawal phase was only 8 weeks. Long-term safety data beyond ~1 year was not reported. Skin hyperpigmentation occurred in all POMC patients, reflecting the melanocortin pathway's role in pigmentation.
How to read the evidence
Phase 3 clinical trials published in The Lancet Diabetes & Endocrinology. While the gold standard for rare diseases, the very small sample sizes and mostly open-label design are limitations inherent to ultra-rare condition studies.
When this study was published
Published in 2020, these are the pivotal trials that led to FDA approval of setmelanotide (IMCIVREE). The drug is now commercially available for these genetic obesity conditions.
The bigger picture
Setmelanotide (brand name IMCIVREE) was approved by the FDA in 2020 based on these trials, becoming the first targeted therapy for genetic obesity. It validated the concept that activating MC4R can treat obesity caused by upstream pathway defects. This has broader implications: researchers are now exploring whether MC4R agonists could help in more common forms of obesity, though the dramatic results seen here may be specific to patients with clear genetic deficiencies.
Questions still open
- Could setmelanotide or similar MC4R agonists be effective in more common forms of obesity involving partial melanocortin pathway dysfunction?
- What is the long-term safety profile of chronic MC4R activation, particularly regarding skin pigmentation and cardiovascular effects?
- Are there other rare genetic obesity syndromes that could benefit from MC4R agonist therapy?
Common questions
What are POMC and LEPR deficiency and why do they cause severe obesity?
How does setmelanotide work differently from GLP-1 weight loss drugs?
Read the original research
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
The lancet. Diabetes & endocrinology, 8(12), 960-970
Citation
Clément, Karine; van den Akker, Erica; Argente, Jesús; Bahm, Allison; Chung, Wendy K; Connors, Hillori; De Waele, Kathleen; Farooqi, I Sadaf; Gonneau-Lejeune, Julie; Gordon, Gregory; Kohlsdorf, Katja; Poitou, Christine; Puder, Lia; Swain, James; Stewart, Murray; Yuan, Guojun; Wabitsch, Martin; Kühnen, Peter. (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.. The lancet. Diabetes & endocrinology, 8(12), 960-970. https://doi.org/10.1016/S2213-8587(20)30364-8